iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes

Diabetes Spectrum : a Publication of the American Diabetes Association
Debbie Hinnen, Jodi Strong

Abstract

Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia, weight gain, or other objections may lead to clinical inertia, whereby therapy is not intensified and patients live with uncontrolled hyperglycemia and increased risk for complications. Initiation of injectable therapy with a glucagon-like peptide (GLP)-1 receptor agonist and/or basal insulin is a recommended option for patients with type 2 diabetes inadequately controlled on one or more oral agents. This article reviews clinical evidence and provides information on dosing and administration of iGlarLixi, a titratable fixed-ratio combination of insulin glargine and the GLP-1 receptor agonist lixisenatide that effectively lowers both fasting and postprandial glucose levels. In phase 3 trials, iGlarLixi provided greater A1C reduction than insulin glargine or lixisenatide alone, without increased hypoglycemia risk compared with insulin glargine. iGlarLixi did not lead to weight gain versus insulin glargine and was associated with a lower frequency of gastrointestinal adverse effects than lixisenatide. iGlarLixi was recently approved by the U.S. Food and Drug Administration to im...Continue Reading

References

Jan 14, 2005·The New England Journal of Medicine·Irl B Hirsch
Feb 22, 2008·Journal of General Internal Medicine·Feng PanA Mark Fendrick
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Feb 9, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·M PeyrotP-M Schumm-Draeger
Mar 23, 2012·Recent Patents on Endocrine, Metabolic & Immune Drug Discovery·Manash P Baruah, Sanjay Kalra
Feb 19, 2013·Diabetes Care·Sarah Stark CasagrandeCatherine C Cowie
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Feb 28, 2014·The New England Journal of Medicine·Amy G EganCurtis Rosebraugh
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Feb 19, 2016·BMJ : British Medical Journal·Laurent AzoulayUNKNOWN Canadian Network for Observational Drug Effect Studies Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Aug 2, 2016·JAMA Internal Medicine·Laurent AzoulayIngrid S Sketris
Sep 23, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Han ChenGuoxin Zhang
Nov 4, 2016·Expert Opinion on Drug Metabolism & Toxicology·Markolf HanefeldLouis Monnier
Nov 25, 2016·Diabetes, Obesity & Metabolism·Lotte M KnapenFrank de Vries
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Jan 21, 2017·Diabetes, Obesity & Metabolism·Heidi StorgaardFilip K Knop

❮ Previous
Next ❯

Citations

Jul 4, 2020·Diabetes, Obesity & Metabolism·Roopa MehtaGregory Fulcher
Jun 22, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Markolf HanefeldJochen Seufert

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01147250
NCT02058147
NCT02058160

Software Mentioned

iGlarLixi

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.